CLCS · Cell Source, Inc.

0001493152-26-015359

SEC filing

Summary

Operating Income was -$3.8M (11.2%) Net Income was -$4.5M (15.2%) Eps was $-0.14 (17.6%)

Key takeaways

Net income narrowed 15.2% to -$4.5M from -$5.3M, benefiting from change in fair value of derivative liability tied to declining common stock value.
Diluted EPS improved 17.6% to -$0.14 from -$0.17, reflecting per-share loss reduction amid ongoing development focus.
Operations remain dependent on debt and equity raises until operations generate sufficient funds, as stated in MD&A.

Full analysis

Net income loss narrowed further by 15.2% to -$4.5 million from -$5.3 million, with diluted EPS improving 17.6% to -$0.14 from -$0.17. The change in fair value of derivative liability, due to the decrease in the Company's common stock value during 2024, contributed positively to this result. Investors should note this non-cash gain reflects stock price dynamics rather than core operational progress, highlighting volatility in biotech financing structures.